RxDoctor Payments Data

Carla Siegfried, MD

Glaucoma Specialist · Saint Louis, MONPI 1457379133

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 96.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $5,540 and has fallen 97.7% since, to $125 in 2025.

$5,956in general payments, 2019–2025

Across 21 payments — averaging $283.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • NEW World Medical,inc.$137
  • Alcon$35
  • Thea Pharma Inc.$28

What the payments were for

  • Consulting fees$3,25055%
  • Travel & lodging$1,59727%
  • Food & beverage$1,10919%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)16$5,755
NEW World Medical,inc.1$137
Alcon2$35
Thea Pharma Inc.2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$257,964
Medicare patients
509
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost186$85,062
RhopressaNetarsudil Mesylate74$43,539
RocklatanNetarsudil Mesylat/Latanoprost91$43,537
Alphagan PBrimonidine Tartrate88$34,906
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol153$30,029
Brimonidine Tartrate594$25,231
CombiganBrimonidine Tartrate/Timolol60$24,184
VyzultaLatanoprostene Bunod28$15,502
Dorzolamide-TimololDorzolamide/Timolol/Pf89$15,337
Latanoprost1,488$13,319
Travoprost82$12,882
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat832$12,473
TafluprostTafluprost/Pf58$11,592
SimbrinzaBrinzolamide/Brimonidine Tart36$10,573
ProlensaBromfenac Sodium12$9,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$5,755$144,152334 claims
AlconSimbrinza, Azopt$35$14,83247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Missourion file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →